FDA Claritin Birth-Defect Review To Take 3 Months; OTC Switch Awaits
Executive Summary
FDA's review of safety and birth registry data to determine whether Schering-Plough's Claritin (loratadine) could be linked to hypospadia is expected to take approximately three months
You may also be interested in...
Schering OTC Claritin Will Launch In December Without Rx Transition Period
Schering-Plough prescription Claritin availability will not overlap with OTC loratadine once the switched drug becomes available in December
Schering OTC Claritin Will Launch In December Without Rx Transition Period
Schering-Plough prescription Claritin availability will not overlap with OTC loratadine once the switched drug becomes available in December
Claritin and hypospadia
FDA review of possible link between loratadine and birth defects "unlikely" to impact its decision on Schering-Plough's NDAs to switch Claritin OTC, agency says, noting many non-Rx products carry labeling restrictions concerning use during pregnancy. In addition to internal review being conducted by Division of Pulmonary & Allergy Drug Products and Office of Drug Safety, agency is consulting with outside experts in review of Swedish data, other information. FDA analysis, which extends to data for Rx Clarinex (desloratadine), could be completed by late September. Separate review by European Agency for the Evaluation of Medicinal Products is ongoing (1"The Tan Sheet" May 6, 2002, p. 3)...